Share

George Church

Ph.D.

Director, NHGRI Center for Excellence in Genomic Science

Robert Winthrop Professor of Genetics, Harvard Medical School

Professor of Health Sciences and Technology, Harvard and MIT

Founding Core Faculty and Lead, Wyss Institute, Harvard University

Dr. Church  is Professor of Genetics at Harvard Medical School and Professor of Health Sciences and Technology at Harvard and the Massachusetts Institute of Technology (MIT), a founding member of the Wyss Institute, and Director of PersonalGenomes.org, the world’s only open-access information on human genomic, environmental, and trait data. Dr. Church is Director of IARPA & NIH BRAIN Projects, and Director of the National Institutes of Health Center for Excellence in Genomic Science. 

Dr. Church is known for pioneering the fields of personal genomics and synthetic biology. He developed the first methods for the first genome sequence & dramatic cost reductions since then (down from $3 billion to $600), contributing to nearly all “next generation sequencing” methods and companies. His team invented CRISPR for human stem cell genome editing and other synthetic biology technologies and applications – including new ways to create organs for transplantation, gene therapies for aging reversal, and gene drives to eliminate Lyme Disease and Malaria. He has co-authored more than 590 papers and 155 patent publications, and one book, “Regenesis”.

He has received numerous awards including the 2011 Bower Award and Prize for Achievement in Science from the Franklin Institute, the Time 100, and election to the National Academy of Sciences and Engineering.

George Church

Ph.D.

Director, NHGRI Center for Excellence in Genomic Science

Robert Winthrop Professor of Genetics, Harvard Medical School

Professor of Health Sciences and Technology, Harvard and MIT

Founding Core Faculty and Lead, Wyss Institute, Harvard University

Dr. Church  is Professor of Genetics at Harvard Medical School and Professor of Health Sciences and Technology at Harvard and the Massachusetts Institute of Technology (MIT), a founding member of the Wyss Institute, and Director of PersonalGenomes.org, the world’s only open-access information on human genomic, environmental, and trait data. Dr. Church is Director of IARPA & NIH BRAIN Projects, and Director of the National Institutes of Health Center for Excellence in Genomic Science. 

Dr. Church is known for pioneering the fields of personal genomics and synthetic biology. He developed the first methods for the first genome sequence & dramatic cost reductions since then (down from $3 billion to $600), contributing to nearly all “next generation sequencing” methods and companies. His team invented CRISPR for human stem cell genome editing and other synthetic biology technologies and applications – including new ways to create organs for transplantation, gene therapies for aging reversal, and gene drives to eliminate Lyme Disease and Malaria. He has co-authored more than 590 papers and 155 patent publications, and one book, “Regenesis”.

He has received numerous awards including the 2011 Bower Award and Prize for Achievement in Science from the Franklin Institute, the Time 100, and election to the National Academy of Sciences and Engineering.

Recent Publications

Progress and limitations in engineering cellular adhesion for research and therapeutics

Published On 2023 Aug 14

Journal article

Intercellular interactions form the cornerstone of multicellular biology. Despite advances in protein engineering, researchers artificially directing physical cell interactions still rely on endogenous cell adhesion molecules (CAMs) alongside off-target interactions and unintended signaling. Recently, methods for directing cellular interactions have been developed utilizing programmable domains such as coiled coils (CCs), nanobody-antigen, and single-stranded DNA (ssDNA). We first discuss...


Fertility restoration in mice with chemotherapy induced ovarian failure using differentiated iPSCs

Published On 2023 Jul 23

Journal article

BACKGROUND: Treatment options for premature ovarian insufficiency (POI) are limited to hormone replacement and donor oocytes. A novel induced pluripotent stem cell (iPSC) transplant paradigm in a mouse model has potential translational applications for management of POI.